Nektar clinical data shows durable responses, but Phase 3 still carries the proof burden

Nektar is a clinical-stage biotech increasingly concentrated around rezpegaldesleukin, moving the drug from Phase 2b validation into registrational development in atopic dermatitis and toward a Phase 3 alopecia areata program. The company has already started two Phase 3 atopic dermatitis trials and has said initial Phase 3 data are expected in mid-2028.

The new information is durability, not initial efficacy. The key addition is six-month off-treatment follow-up in alopecia areata, where the company says hair regrowth continued and deepened through one year of treatment, with those effects continuing off treatment for most patients. 〔0〕 This is more meaningful than another short-term response snapshot because durability is a central weakness of existing alopecia areata therapies.

The atopic dermatitis update reinforces the same mechanism across dosing schedules. Monthly and quarterly maintenance dosing reportedly produced new as well as sustained responses across EASI-75, vIGA-AD 0/1 and itch measures, with some patients reaching complete skin clearance. That supports the commercial and clinical thesis that a Treg-based treatment might offer lasting disease control with less-frequent dosing, although the filing provides no detailed response rates or statistical comparisons for this update.

This advances the development story, but does not remove the main risk. The direction was partly known: Nektar previewed the EADV presentations on September 28, 2026, and previously reported positive Phase 2b maintenance results in atopic dermatitis. The incremental value is the confirmation of longer-duration benefit in alopecia areata and a broader cross-indication durability narrative. The remaining proof burden is Phase 3 execution, where the company must reproduce these effects in larger, controlled studies; Nektar says the alopecia areata Phase 3 program is planned for early 2027. 〔1〕

Bottom line: This is a genuine strengthening of Nektar’s lead-drug story, especially because durability was shown beyond active treatment in alopecia areata. It improves the Phase 3 setup across two indications, but remains supportive clinical evidence rather than a definitive regulatory or commercial validation.